News & Updates
Showing Urology articles
Showing
Show Multimedia Only

Erdafitinib prevails in bladder cancer with select FGFRalt
22 Jun 2023
byAudrey Abella
The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.
22 Jun 2023

Does extended lymph node sampling increase complications?
06 Jun 2023
Patients undergoing more extensive lymph node sampling during surgery for a suspected malignant paediatric renal tumour do not appear to have a higher likelihood of experiencing clinically significant complications, reveals a study.
06 Jun 2023






